Email
RSS10/11/08 - 20:18 ... source : National Institutes of Health - NIH
... disease — the leading cause of death for both men and women. Although we have made great strides in preventing and treating heart disease, we continue to explore the complex mechanisms involved in cardiovascular disease, ...
10/11/08 - 18:38 ... source : MobileAccess
... 0 false false false EN-US X-NONE X-NONE Vienna, Va. — November 10, 2008—MobileAccess, a global provider of enterprise wireless solutions, in partnership with Sprint (NYSE:S) has extended the MobileAccess Universal Wireless Network to Clarian Health's ...
10/11/08 - 17:40 ... source : Unicef
... date by subject by region Hot topics UNICEF's positions Press centre News note Measles Initiative supports disease prevention for children in China’s earthquake zone Providing life-saving immunization in aftermath of earthquake WASHINGTON, D.C, 10 November ...
10/11/08 - 13:34 ... source : DiaGenic
... ASA, Grenseveien 92, NO-0663 Oslo, Norway Tel +47 95939918 Email: erik.christensen@diagenic.com Media Inquiries For DiaGenic Richard Hayhurst, Hayhurst Media Tel +44 (0) 7711821527 Email: richard@hayhurstmedia.com For Applied Biosystems Renaldo Juanso Applied Biosystems Tel +001 650.638.5354 ...
09/11/08 - 21:12 ... source : Thomson Healthcare
... 2008 - Thomson Reuters announced today that St. Peter's Hospital in Albany, NY, has significantly improved its core measures processes -- such as increasing its discharge instruction compliance for heart failure patients from 85.4 percent ...
07/11/08 - 20:49 ... source : American Academy of Pediatrics - AAP
... scientific evidence required to understand and implement practice-based preventive oral health programs designed to improve oral health outcomes for all children and especially children at significant risk of dental decay. Additionally, it reviews cariology and ...
07/11/08 - 10:05 ... source : Genentech
... Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment -- South San Francisco, Calif. and Melville, New York -- November 6, 2008 -- Genentech, Inc., (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: ...
07/11/08 - 09:25 ... source : Santhera Pharmaceuticals
... company focused on neuromuscular diseases, today announced preclinical data on a novel generation of melanocortin-4 (MC4) receptor antagonists for potential treatment of cancer cachexia (severe muscle wasting). The most advanced candidates significantly increase food intake ...
07/11/08 - 07:40 ... source : Streamline Health
07/11/08 - 05:06 ... source : Theratechnologies
... today that new 26-week data from a combined analysis of both its Phase 3 clinical trials testing tesamorelin in HIV-associated lipodystrophy were presented as a poster (Post ...
